Damora Therapeutics (DMRA) Net Cash Flow (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Net Cash Flow data on file, last reported at $275.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 11571.71% year-over-year to $275.3 million; the trailing twelve-month figure through Mar 2026 stood at $271.0 million (up 3077.97% YoY), and the FY2025 full-year result was $242.7 million, up 3592.72% from the prior year.
• Net Cash Flow for Q1 2026 stood at $275.3 million, up from $574000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $275.3 million in Q1 2026 and bottomed at -$17.0 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$2.1 million (2023), against an average of $12.9 million.
• The widest annual swing landed in 2024, when Net Cash Flow tumbled 184450.0%; it then jumped 11571.71% in 2026.
• A 5-year view of Net Cash Flow shows it stood at $2.9 million in 2022, then sank by 163.9% to -$1.9 million in 2023, then sank by 160.91% to -$4.9 million in 2024, then soared by 111.68% to $574000.0 in 2025, then jumped by 47865.33% to $275.3 million in 2026.
• The last three Net Cash Flow figures came in at $275.3 million (Q1 2026), $574000.0 (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.

Peer Comparison